Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0194 • ACR Convergence 2020
Depression Symptoms but Not Clinically Diagnosed Depression Predict Mortality in Rheumatoid Arthritis
Jose Felix Restrepo¹, Inmaculada Del Rincon¹ and Agustin Escalante¹, ¹University of Texas Health Science Center at San Antonio/ Department of Medicine/ Rheumatology, San Antonio, TX
Background/Purpose: Depression and depressive symptoms are common but under-recognized in rheumatoid arthritis (RA). Few studies have examined depression symptoms in RA patients compared to clinically…
Abstract Number: 0210 • ACR Convergence 2020
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Inhibitors
Roy Fleischmann¹, Karina Maslova², Henry Leher³, Amy Praestgaard² and Gerd Burmester⁴, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Sanofi, Cambridge, MA, ³Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁴Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Sarilumab is a human IL-6 receptor (IL-6R) inhibitor approved for the treatment of adults with moderate to severely active RA. In the TARGET study…
Abstract Number: 0227 • ACR Convergence 2020
Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors
Lucía Vega-Álvarez¹, Itziar Calvo-Zorrilla¹, Oihane Ibarguengoitia-Barrena¹, Juan M. Blanco-Madrigal¹, David Montero-Seisdedos², Carmen L. Garcia-Gomez¹, Maria Esther Ruiz-Lucea¹, Ana R. Inchaurbe-Pellejero¹, Ignacio Torre-Salaberri¹, Clara E. Perez-Velasquez¹, Olaia Fernandez-Berrizbeitia¹, Eduardo Cuende-Quintana³, Iñigo R. Gorostiza-Hormaetxe⁴, María Luz García-Vivar¹ and Eva Galindez-Agirregoikoa¹, ¹Basurto University Hospital, BILBAO, Spain, ²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ³Basurto University Hospital, Madrid, Spain, ⁴Basurto University Hospital, Bilbao
Background/Purpose: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of…
Abstract Number: 0343 • ACR Convergence 2020
Co-expression of DC-STAMP and CX3CR1: Biomarkers for Tissue Resident Osteoclasts in Psoriatic Arthritis
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno², Ananta Paine³, Benjamin Korman³, Marc Nuzzo⁴, Lihi Eder⁵ and Christopher Ritchlin³, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, ⁵Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) patients often experience joint damage mediated by osteoclasts (OC). Although PsA pathogenesis is poorly understood, the production of the cytokines IL-17,…
Abstract Number: 0487 • ACR Convergence 2020
Association Between an Extended Lifestyle Score and Adverse Health-related Outcomes in People with Rheumatoid Arthritis: A Study of 5295 UK Biobank Participants
Jordan Canning¹, Stefan Siebert², Bhautesh Jani¹, Frances Mair¹ and Barbara Nicholl¹, ¹University of Glasgow, Glasgow, Scotland, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterised by inflammation of the synovial joints. Traditional lifestyle factors, such as smoking and poor diet,…
Abstract Number: 0611 • ACR Convergence 2020
Disease Activity and Disability Are Not Associated with Rehabilitation Utilization in African Americans with Rheumatoid Arthritis
Louise Thoma¹, Rebecca Cleveland², S. Louis Bridges³, Beth Jonas¹ and Leigh Callahan⁴, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³University of Alabama at Birmingham, Mountain Brk, AL, ⁴University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: Considerable advances in pharmacological care for adults with rheumatoid arthritis (RA) over the last 25 years have reduced disease activity in individual patients, but…
Abstract Number: 0752 • ACR Convergence 2020
Serum Proteomics Implicates Neutrophil Degranulation in Rheumatoid Arthritis Disease Activity
Liam O'Neil¹, Vidyanand Anaparti¹, Dana Wiens¹, Irene Smolik¹, Xiaobo Meng¹ and Hani El-Gabalawy¹, ¹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Though targeted therapeutics have improved outcomes in Rheumatoid Arthritis (RA) treatment, the understanding of the underlying biological mechanisms that mediate inflammatory arthritis in RA…
Abstract Number: 0769 • ACR Convergence 2020
Does the Autoantibody-Response Mature Between Presentation with Arthralgia and Development of Rheumatoid Arthritis? – a Longitudinal Serological Study
Fenne Wouters¹, Ellis Niemantsverdriet¹, Nazike Salioska¹, Annemarie Dorjée¹, René Toes¹ and Annette van der Helm - van Mil², ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Auto-antibodies in rheumatoid arthritis (RA) are often present years before disease onset but their mere presence does not seem enough to induce RA. Several…
Abstract Number: 0786 • ACR Convergence 2020
A Combination of Dimensionality Reduction Techniques Reveals Novel HLA-DR+ ‘Candidate’ Antigen-Presenting Cell Subsets (cAPC) in Patients with Rheumatoid Arthritis (RA)
Christian Geier¹, Jon Giles¹, Samantha Gaines², Christopher Depender¹, Joan Bathon¹ and Robert Winchester¹, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: The presentation of MHC-peptide complexes to T lymphocytes via antigen-presenting cells (APC) is a crucial step in the initiation of immune responses. Dendritic cells…
Abstract Number: 0803 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety
Mitsumasa Kishimoto¹, Yoshiya Tanaka², Leslie Harrold³, Alina Onofrei³, Christine Barr⁴, Ekta Agarwal⁵, Jose L Rivas⁶, Naonobu Sugiyama⁷, Jeffrey Greenberg⁸ and Hisashi Yamanaka⁹, ¹Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Albany, NY, ⁵Pfizer, Inc., Princeton Jct, NJ, ⁶Pfizer SLU, Madrid, Spain, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Corrona, LLC and NYU School of Medicine, Waltham, MA, ⁹Sanno Medical Center, Tokyo, Japan, Tokyo, Japan
Background/Purpose: There is limited information on the real-world safety of disease-modifying anti-rheumatic drugs (DMARDs) approved for treating rheumatoid arthritis (RA) in Japan. Using a Japanese…
Abstract Number: 0820 • ACR Convergence 2020
High Remission Rates in RA – Real Life Data from Bariticinib
Sara Bayat¹, Koray Tascilar², Arnd Kleyer², David Simon², Axel Hueber³ and Georg Schett⁴, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ³Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Recent developments of targeted treatments such as targeted synthetic DMARDs (tsDMARDs) increase the chances of a sustained low disease activity (LDA) or remission state…
Abstract Number: 0940 • ACR Convergence 2020
In Patients with Inflammatory Arthritides Central Pain Sensitization Is Strictly Associated with Functional Disability
Giovanni Adami¹, Angelo Fassio¹, Elisabetta Gerratana², Alessandro Giollo¹, Camilla Benini¹, Luca Idolazzi¹, Elisabetta Vantaggiato¹, Davide Gatti¹ and Maurizio Rossini¹, ¹Rheumatology Unit, University of Verona, Verona, Italy, ²Rheumatology Unit, University of Messina, Messina, Italy
Background/Purpose: Long-term nociceptive pain, as in inflammatory arthritides, can cause Central Sensitization (CS) to pain. CS Inventory (CSI) is a validated screening instrument for clinicians to…
Abstract Number: 1001 • ACR Convergence 2020
Risk of Malignant Melanoma and Nonmelanoma Skin Cancer in Rheumatoid Arthritis Patients Initiating Methotrexate versus Hydroxychloroquine
Hemin Lee¹, Sarah Chen², Nileesa Gautam², Seanna Vine¹, Mengdong He², Rishi Desai², Michael Weinblatt¹, Robert Glynn² and Seoyoung Kim², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston
Background/Purpose: Previous randomized clinical trials and observational studies have signaled an increased risk of skin cancer in rheumatoid arthritis (RA) patients treated with immunosuppressants such…
Abstract Number: 1017 • ACR Convergence 2020
Racial and Ethnic Disparities in the Risk of Preterm Birth Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis with Varying Reference Groups
Lena Sabih¹, Jennifer Strouse¹, Gretchen Bandoli², Rebecca Baer³, Laura Jelliffe-Pawlowski³, Christina Chambers², Namrata Singh⁴ and Kelli Ryckman⁵, ¹University of Iowa Hospitals and Clinics, Iowa City, IA, ²University of California San Diego, La Jolla, CA, ³University of California San Francisco, San Francisco, ⁴University of Washington, Bellevue, WA, ⁵University of Iowa, Iowa City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are independently associated with preterm birth (PTB). Black women have higher risk of both ARD and…
Abstract Number: 1188 • ACR Convergence 2020
Serum Anti-malondialdehyde-acetaldehyde IgA Antibody Concentration Improves Prediction of Coronary Atherosclerosis Beyond Traditional Risk Factors in Patients with Rheumatoid Arthritis
Hannah Lomzenski¹, Geoffrey Thiele², Michael Duryee², Sheau-Chiann Chen¹, Fei Ye¹, Ted Mikuls², C. Michael Stein¹ and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased cardiovascular disease (CVD) independent of traditional risk factors. Oxidative stress is increased in patients with RA and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].